Home › Drug Codes › J Codes › J0178 · EYLEA
Updated July 1st, 2026

EYLEA J Code: J0178

Injection, aflibercept, 1 mg

Login to unlock all benchmarks

Q4 2026 Medicare Payment Limit for J0178, effective October 1, 2026: $722.251 per HCPCS billing unit, down 2.9% from $743.605. From CMS's final file.

?
Medicare Payment Limit ?
$743.605
/ HCPCS billing unit · Q3 2026
APC Payment Limit ?
$743.605
/ HCPCS billing unit · APC 1420
ASP ?
$•••.••
Login to view
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
2
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, aflibercept, 1 mg
HCPCS Added Date January 1, 2013
Manufacturer Regeneron Pharmaceuticals
Route of Administration Intravitreal
Generic Status Single-Source; Branded
Dosage Type Single-Dose
Dosage Form Injection, Solution

About EYLEA

Eylea is a medication aligned to the HCPCS J Code: J0178 for billing, pricing, and reimbursement purposes in the United States. It is an Ophthalmology drug administered via the intravitreal route and manufactured by Regeneron Pharmaceuticals.

According to CMS Drug Use Information: Aflibercept is used to treat certain serious eye conditions (such as macular edema/degeneration, diabetic retinopathy, retinopathy of prematurity). This medication can help preserve vision and prevent blindness. Aflibercept belongs to a class of drugs known as growth factor inhibitors. It works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels. This monograph is about the following aflibercept products: aflibercept, aflibercept-ayyh.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code Drug Manufacturer Billing Units / Pkg Package Size
61755-0005-01 Eylea Regeneron Pharmaceuticals, Inc. 2 2 MG / 0.05 ML
61755-0005-02 Eylea Regeneron Pharmaceuticals, Inc. 2 2 MG / 0.05 ML
Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

EYLEA Pricing & Reimbursement

J0178 Private Payer Reimbursement
$777.99 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →
UnitedHealthcare, BlueCross BlueShield, Aetna, Cigna

Historical Graphing and Billing Calculator

per HCPCS unit
As of Q3 2026

Aflibercept Biosimilar Information:

EYLEA Approval Date: November 18, 2011

Product Name HCPCS Code Active Ingredient BLA Type
Eylea J0178 Aflibercept 351(a) Originator Product
Opuviz Q5153 Aflibercept 351(k) Interchangeable
Yesafili Q5155 Aflibercept 351(k) Interchangeable
Ahzantive Q5150 Aflibercept 351(k) Biosimilar
Enzeevu Q5149 Aflibercept 351(k) Biosimilar
Pavblu Q5147 Aflibercept 351(k) Biosimilar
Eydenzelt Q5170 Aflibercept 351(k) Biosimilar

EYLEA CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
67028 Intravitreal injection of a pharmacologic agent (separate procedure) 67028
JW / JZ modifiers apply

CMS has identified Eylea (J0178) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

EYLEA Medically Unlikely Edits (MUE)

The most billing units of J0178 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg.

Practitioner Office & Hospital Outpatient
4 units / day
= 4 mg per day

MAI 2 · Date of Service Edit: Policy. Absolute per-day limit set by policy or regulation; units above it are not payable, and denials are not appealable on medical-necessity grounds. See all MUE limits →

mg Enter a dose to see how many billing units it is and whether it is under the limit.

EYLEA Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema Following Retinal Vein Occlusion (RVO) Neovascular (Wet) Age-Related Macular Degeneration (AMD) Retinopathy of Prematurity (ROP)
Drug Class
Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Eylea billing and coding guide?
Billing and coding information for EYLEA can be found through Regeneron. Visit Here →
Are there any available Eylea patient assistance programs?
EYLEA patient assistance information can be found through Regeneron. Visit Here →
Where can I find Eylea prescribing information?
EYLEA prescribing information can be found at the link below: Visit Here →
Where can I find Eylea side effect information?
Information regarding EYLEA's side effects can be found at MedlinePlus Visit Here →
Does billing EYLEA require JZ/JW wastage modifiers?
CMS has identified EYLEA(J0178) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.